ALCLOMETASONE DIPROPIONATO (LEGEDERM®) NEL TRATTAMENTO DELLE DERMATOSI STEROIDO-SENSIBILI DELL'ANZIANO

Translated title of the contribution: Alclometasone dipropionate (Legederm®) in the treatment of steroid-sensitive skin diseases in geriatric patients

A. Morresi, M. Simonacci, G. Mozzicafreddo, A. Giacchetti, P. Criante, V. Mambelli, S. Sisti, E. Marchesi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This is a randomized single blind parallel comparison of alclometasone dipropionate cream 0.1% vs hydrocortisone butyrrate in 39 geriatric patients (>60 years old) with steroid sensible skin diseases. The regimen consisted of dosing patients with two applications of the two drugs every day for 4 weeks. Follow-up evaluations have been done weekly, and subjective and objective clinical symptoms, adherence to the study protocol, evolution of the disease, onset of adverse reactions including atrophy have been recorded. Furthermore possible side-effects on hypophysis-adrenal axis have been monitored in baseline conditions, after 7 days and at the end of therapy. In most patients bioptic skin patterns for histomorphometric examination have been drawn before and after therapy to be evaluated by a blind examinator. Alclometasone has reduced initial skin lesions by 82.2%, the extent as hydrocortisone butyrrate. In five patients the complete clearance of the disease has been obtained. Study drugs have been tolerated well by all patients, nor clinical signs of atrophy have been observed. Fluctuations of blood cortisol levels ranged between the normal values. In patients treated with alclometasone histomorphometry revealed a better skin trophism than in patients treated with hydrocortisone butyrrate.

Original languageItalian
JournalGiornale Italiano di Dermatologia e Venereologia
Volume125
Issue number6
Publication statusPublished - 1990

Fingerprint

Skin Diseases
Geriatrics
Steroids
Hydrocortisone
Skin
Therapeutics
Atrophy
Pituitary Gland
alclometasone dipropionate
Pharmaceutical Preparations
Reference Values

ASJC Scopus subject areas

  • Dermatology

Cite this

ALCLOMETASONE DIPROPIONATO (LEGEDERM®) NEL TRATTAMENTO DELLE DERMATOSI STEROIDO-SENSIBILI DELL'ANZIANO. / Morresi, A.; Simonacci, M.; Mozzicafreddo, G.; Giacchetti, A.; Criante, P.; Mambelli, V.; Sisti, S.; Marchesi, E.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 125, No. 6, 1990.

Research output: Contribution to journalArticle

Morresi, A, Simonacci, M, Mozzicafreddo, G, Giacchetti, A, Criante, P, Mambelli, V, Sisti, S & Marchesi, E 1990, 'ALCLOMETASONE DIPROPIONATO (LEGEDERM®) NEL TRATTAMENTO DELLE DERMATOSI STEROIDO-SENSIBILI DELL'ANZIANO', Giornale Italiano di Dermatologia e Venereologia, vol. 125, no. 6.
Morresi, A. ; Simonacci, M. ; Mozzicafreddo, G. ; Giacchetti, A. ; Criante, P. ; Mambelli, V. ; Sisti, S. ; Marchesi, E. / ALCLOMETASONE DIPROPIONATO (LEGEDERM®) NEL TRATTAMENTO DELLE DERMATOSI STEROIDO-SENSIBILI DELL'ANZIANO. In: Giornale Italiano di Dermatologia e Venereologia. 1990 ; Vol. 125, No. 6.
@article{6bcd7844c3e74c1c8c0aa809794d17fc,
title = "ALCLOMETASONE DIPROPIONATO (LEGEDERM{\circledR}) NEL TRATTAMENTO DELLE DERMATOSI STEROIDO-SENSIBILI DELL'ANZIANO",
abstract = "This is a randomized single blind parallel comparison of alclometasone dipropionate cream 0.1{\%} vs hydrocortisone butyrrate in 39 geriatric patients (>60 years old) with steroid sensible skin diseases. The regimen consisted of dosing patients with two applications of the two drugs every day for 4 weeks. Follow-up evaluations have been done weekly, and subjective and objective clinical symptoms, adherence to the study protocol, evolution of the disease, onset of adverse reactions including atrophy have been recorded. Furthermore possible side-effects on hypophysis-adrenal axis have been monitored in baseline conditions, after 7 days and at the end of therapy. In most patients bioptic skin patterns for histomorphometric examination have been drawn before and after therapy to be evaluated by a blind examinator. Alclometasone has reduced initial skin lesions by 82.2{\%}, the extent as hydrocortisone butyrrate. In five patients the complete clearance of the disease has been obtained. Study drugs have been tolerated well by all patients, nor clinical signs of atrophy have been observed. Fluctuations of blood cortisol levels ranged between the normal values. In patients treated with alclometasone histomorphometry revealed a better skin trophism than in patients treated with hydrocortisone butyrrate.",
author = "A. Morresi and M. Simonacci and G. Mozzicafreddo and A. Giacchetti and P. Criante and V. Mambelli and S. Sisti and E. Marchesi",
year = "1990",
language = "Italian",
volume = "125",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - ALCLOMETASONE DIPROPIONATO (LEGEDERM®) NEL TRATTAMENTO DELLE DERMATOSI STEROIDO-SENSIBILI DELL'ANZIANO

AU - Morresi, A.

AU - Simonacci, M.

AU - Mozzicafreddo, G.

AU - Giacchetti, A.

AU - Criante, P.

AU - Mambelli, V.

AU - Sisti, S.

AU - Marchesi, E.

PY - 1990

Y1 - 1990

N2 - This is a randomized single blind parallel comparison of alclometasone dipropionate cream 0.1% vs hydrocortisone butyrrate in 39 geriatric patients (>60 years old) with steroid sensible skin diseases. The regimen consisted of dosing patients with two applications of the two drugs every day for 4 weeks. Follow-up evaluations have been done weekly, and subjective and objective clinical symptoms, adherence to the study protocol, evolution of the disease, onset of adverse reactions including atrophy have been recorded. Furthermore possible side-effects on hypophysis-adrenal axis have been monitored in baseline conditions, after 7 days and at the end of therapy. In most patients bioptic skin patterns for histomorphometric examination have been drawn before and after therapy to be evaluated by a blind examinator. Alclometasone has reduced initial skin lesions by 82.2%, the extent as hydrocortisone butyrrate. In five patients the complete clearance of the disease has been obtained. Study drugs have been tolerated well by all patients, nor clinical signs of atrophy have been observed. Fluctuations of blood cortisol levels ranged between the normal values. In patients treated with alclometasone histomorphometry revealed a better skin trophism than in patients treated with hydrocortisone butyrrate.

AB - This is a randomized single blind parallel comparison of alclometasone dipropionate cream 0.1% vs hydrocortisone butyrrate in 39 geriatric patients (>60 years old) with steroid sensible skin diseases. The regimen consisted of dosing patients with two applications of the two drugs every day for 4 weeks. Follow-up evaluations have been done weekly, and subjective and objective clinical symptoms, adherence to the study protocol, evolution of the disease, onset of adverse reactions including atrophy have been recorded. Furthermore possible side-effects on hypophysis-adrenal axis have been monitored in baseline conditions, after 7 days and at the end of therapy. In most patients bioptic skin patterns for histomorphometric examination have been drawn before and after therapy to be evaluated by a blind examinator. Alclometasone has reduced initial skin lesions by 82.2%, the extent as hydrocortisone butyrrate. In five patients the complete clearance of the disease has been obtained. Study drugs have been tolerated well by all patients, nor clinical signs of atrophy have been observed. Fluctuations of blood cortisol levels ranged between the normal values. In patients treated with alclometasone histomorphometry revealed a better skin trophism than in patients treated with hydrocortisone butyrrate.

UR - http://www.scopus.com/inward/record.url?scp=0025169044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025169044&partnerID=8YFLogxK

M3 - Articolo

C2 - 2279745

AN - SCOPUS:0025169044

VL - 125

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -